nach oben

Die Gastroenterologie

Erschienen in:

03.02.2017 | Reizdarmsyndrom | Schwerpunkt

Reizdarm und Reizmagen – Pathophysiologie und Biomarker

verfasst von: Prof. Dr. rer. nat. M. Schemann

Erschienen in: Die Gastroenterologie | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Funktionelle Magendarmerkrankungen, wie Reizdarm oder Reizmagen, gehören zu den häufigsten Gründen, warum Patienten den Arzt aufsuchen. Diagnose und gezielte Therapie bleiben bis heute eine große Herausforderung. Beide Syndrome werden bisher rein symptomenbasiert nach Ausschlussdiagnose diagnostiziert. Inzwischen ist aber klar, dass Reizdarm und Reizmagen mit definierten strukturellen, molekularen, genetischen, immunologischen, nervalen und psychosozialen Veränderungen assoziiert sind. Symptome werden durch Stress, Motilitätsstörungen, gastrointestinale Infektionen, Immunaktivierung sowie erhöhte mechanische und chemische Sensibilität ausgelöst bzw. verschlimmert. Die vielen heute bekannten Pathomechanismen spiegeln zum einen den multifaktoriellen Charakter wider, sind zum anderen aber auch Hinweise auf pathophysiologisch unterschiedliche Erkrankungssubtypen. Es ist zu erwarten, dass die weitere Aufklärung pathophysiologisch relevanter Faktoren und deren Clusteranalyse und Korrelation mit den klinischen Symptomen die Diagnostik und Therapie funktioneller Magen-Darm-Erkrankungen verbessert. In Zukunft könnten Biomarker helfen, Patienten besser zu klassifizieren und damit eine spezifische Therapieentscheidung zu ermöglichen.

Akbar A, Yiangou Y, Facer P et al (2008) Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57:923–929CrossRefPubMedPubMedCentral

Andresen V, Montori VM, Keller J et al (2008) Effects of 5‑hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: A systematic review and metaanalysis of randomized controlled trials. Clin Gastroenterol Hepatol 6:545–555CrossRefPubMedPubMedCentral

Atkinson W, Lockhart S, Whorwell PJ et al (2006) Altered 5‑hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 130:34–43CrossRefPubMed

Berdún S, Rychter J, Vergara P (2015) Effects of nerve growth factor antagonist K252a on peritoneal mast cell degranulation: Implications for rat postoperative ileus. Am J Physiol Gastrointest Liver Physiol 309:G801–G806PubMed

Buhner S, Li Q, Vignali S, Barbara G (2009) Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 137:1425–1434CrossRefPubMed

Buhner S, Li Q, Berger T et al (2012) Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. Neurogastroenterol Motil 24:1134–e572CrossRefPubMed

Buhner S, Braak B, Li Q et al (2014) Neuronal activation by mucosal biopsy supernatants from irritable bowel syndrome patients is linked to visceral sensitivity. Exp Physiol 2014:1299–1311CrossRef

Camilleri M, McKinzie S, Busciglio I et al (2008) Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6:772–781CrossRefPubMedPubMedCentral

Camilleri M (2012) Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367:1626–1635CrossRefPubMed

10.

Camilleri M (2014) Physiological underpinnings of irritable bowel syndrome: Neurohormonal mechanisms. J Physiol 592:2967–2980CrossRefPubMedPubMedCentral

11.

Camilleri M, Shin A, Busciglio I et al (2014) Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil 26:1677–1685CrossRefPubMedPubMedCentral

12.

Camilleri M (2015) Biomarkers and personalized therapy in lower functional gastrointestinal disorders. Aliment Pharmacol Ther 42:818–828CrossRefPubMedPubMedCentral

13.

Celli J, Rappold G, Niesler B (2016) The Human Serotonin Type 3 Receptor Gene (HTR3A-E) Allelic Variant Database. Hum Mutat. doi:10.1002/humu.23136 PubMed

14.

Cenac N, Andrews CN, Holzhausen M et al (2007) Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117:636–647CrossRefPubMedPubMedCentral

15.

Choi YJ, Kim N, Kim J et al (2016) Upregulation of Vanilloid Receptor-1 in functional dyspepsia with or without Helicobacter pylori infection. Medicine (Baltimore) 95:e3410CrossRef

16.

Cirillo C, Bessissow T, Desmet AS et al (2015) Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol 110:1205–1215CrossRefPubMed

17.

Collins SM, Chang C, Mearin F (2012) Postinfectious chronic gut dysfunction: From bench to bedside. Am J Gastroenterol Suppl 1:2–8CrossRef

18.

Czogalla B, Schmitteckert S, Houghton LA et al (2015) A meta-analysis of immunogenetic case-control association studies in irritable bowel syndrome. Neurogastroenterol Motil 27:717–727CrossRefPubMed

19.

Cremon C, Gargano L, Morselli-Labate AM et al (2009) Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms. Am J Gastroenterol 104:392–400CrossRefPubMed

20.

Dothel G, Barbaro MR, Boudin H et al (2015) Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 148:1002–1011CrossRefPubMed

21.

Ek WE, Reznichenko A, Ripke S et al (2015) Exploring the genetics of irritable bowel syndrome: A GWA study in the general population and replication in multinational case-control cohorts. Gut 64:1774–1782CrossRefPubMed

22.

El-Salhy M (2012) Irritable bowel syndrome: Diagnosis and pathogenesis. World J Gastroenterol 18:5151–5163CrossRefPubMedPubMedCentral

23.

El-Salhy M, Gilja OH, Gundersen D et al (2014) Duodenal Chromogranin A cell density as a Biomarker for the diagnosis of irritable bowel syndrome. Gastroenterol Res Pract 462856. doi:10.1155/2014/462856

24.

El-Salhy M, Hatlebakk JG, Gilja OH et al (2015) Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides 67:12–19CrossRefPubMed

25.

Gonlachanvit S, Mahayosnond A, Kullavanijaya P (2009) Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: Evidence for capsaicin-sensitive visceralnociception hypersensitivity. Neurogastroenterol Motil 21:23–32CrossRefPubMed

26.

Guarino MP, Barbara G, Cicenia A et al (2016) Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. Neurogastroenterol Motil. doi:10.1111/nmo.12928

27.

Gupta S (2016) Infectious disease: Something in the water. Nature 533:114–115CrossRef

28.

Hammer J, Führer M, Pipal L et al (2008) Hypersensitivity for capsaicin in patients with functional dyspepsia. Neurogastroenterol Motil 20:125–133PubMed

29.

Hausken T, Berstad A (1992) Wide gastric antrum in patients with non-ulcer dyspepsia. Effect of cisapride. Scand J Gastroenterol 27:427–432CrossRefPubMed

30.

Henström M, Diekmann L, Bonfiglio F et al (2016) Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut. doi:10.1136/gutjnl-2016-312456

31.

Hughes PA, Harrington AM, Castro J et al (2013) Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes. Gut 62:1456–1465CrossRefPubMed

32.

Kourikou A, Karamanolis GP, Dimitriadis GD et al (2015) Gene polymorphisms associated with functional dyspepsia. World J Gastroenterol 21:7672–7682CrossRefPubMedPubMedCentral

33.

Lacy BE, Mearin F, Chang L et al (2016) Bowel disorders. Gastroenterology 150:1393–1407CrossRef

34.

Larsson MH, Simren M, Thomas EA et al (2007) Elevated motility-related transmucosal potential difference in the upper small intestine in their irritable bowel syndrome. Neurogastroenterol Motil 19:812–820CrossRefPubMed

35.

Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M, Enck P, Frieling T, Haag S, Holtmann G, Karaus M, Kathemann S, Keller J, Kuhlbusch-Zicklam R, Kruis W, Langhorst J, Matthes H, Mönnikes H, Müller-Lissner S, Musial F, Otto B, Rosenberger C, Schemann M, van der Voort I, Dathe K, Preiss JC (2011) Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z Gastroenterol 49:237–293CrossRefPubMed

36.

Lee KJ, Tack J (2010) Duodenal Implications in the Pathophysiology of Functional Dyspepsia. J Neurogastroenterol Motil 16:251–257CrossRefPubMedPubMedCentral

37.

Mayer EA, Gupta A, Kilpatrick LA et al (2015) Imaging brain mechanisms in chronic visceral pain. Pain 156:50–63CrossRef

38.

Mearin F, Cucala M, Azpiroz F et al (1991) The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 101:999–1006CrossRefPubMed

39.

Mertz H, Naliboff B, Munakata J et al (1995) Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 109:40–52CrossRefPubMed

40.

Munakata J, Naliboff B, Harraf F et al (1997) Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 112:55–63CrossRefPubMed

41.

Ostertag D, Buhner S, Michel K et al (2015) Reduced responses of Submucous neurons from irritable bowel syndrome patients to a cocktail containing histamine, serotonin, TNFα, and Tryptase (IBS-cocktail). Front Neurosci 9:465CrossRefPubMedPubMedCentral

42.

Oustamanolakis P, Tack J (2012) Dyspepsia organic versus functional. J Clin Gastroenterol 46:175–190CrossRefPubMed

43.

Piche T, Barbara G, Aubert P et al (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators. Gut 58:196–201CrossRefPubMed

44.

Pike BL, Paden KA, Alcala AN et al (2015) Immunological Biomarkers in Postinfectious irritable bowel syndrome. J Travel Med 22:242–250CrossRefPubMed

45.

Pilichiewicz AN, Feltrin KL, Horowitz M et al (2008) Functional dyspepsia is associated with a greater symptomatic response to fat but not carbohydrate, increased fasting and postprandial CCK, and diminished PYY. Am J Gastroenterol 103:2613–2623CrossRefPubMed

46.

Scanzi J, Accarie A, Muller E et al (2016) Colonic overexpression of the T‑type calcium channel Cav3.2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients. Neurogastroenterol Motil 28:1632–1640CrossRefPubMed

47.

Schemann M, Camilleri M (2013) Functions and imaging of mast cell and neural axis of the gut. Gastroenterology 144:698–704CrossRefPubMedPubMedCentral

48.

Serra J, Azpiroz F, Malagelada JR (1995) Perception and reflex responses to intestinal distention in humans are modified by simultaneous or previous stimulation. Gastroenterology 109:1742–1749CrossRefPubMed

49.

Spiller R, Lam C (2012) An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered Microbiome. J Neurogastroenterol Motil 18:258–268CrossRefPubMedPubMedCentral

50.

Stanghellini V, Chan F, Hasler WL et al (2016) Gastroduodenal disorders. Gastroenterology 150:1380–1392CrossRefPubMed

51.

Swan C, Duroudier NP, Campbell E et al (2013) Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFα. Gut 62:985–994CrossRefPubMed

52.

Talley NJ, Ford AC (2015) Functional dyspepsia. N Engl J Med 373:1853–1863. doi:10.1056/NEJMra1501505 CrossRefPubMed

53.

Tanaka F, Tominaga K, Fujikawa Y et al (2016) Concentration of Glial cell line-derived Neurotrophic factor positively correlates with symptoms in functional dyspepsia. Dig Dis Sci 61:3478–3485CrossRefPubMed

54.

van Wanrooij SJM, Wouters MM, Van Oudenhove L et al (2014) Sensitivity testing in Irritable Bowel Syndrome with rectal capsaicin stimulations: Role of TRPV1 upregulation and sensitization in visceral hypersensitivity. Am J Gastroenterol 109:99–109CrossRefPubMed

55.

Van Oudenhove L, Törnblom H, Störsrud S et al (2016) Depression and Somatization are associated with increased postprandial symptoms in patients with irritable bowel syndrome. Gastroenterology 150:866–874CrossRefPubMed

56.

Whitehead WE, Holtkotter B, Enck P et al (1990) Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 98:1187–1192CrossRefPubMed

57.

Witte AB, Walker MM, Talley NJ et al (2016) Decreased number of duodenal endocrine cells with unaltered serotonin-containing cells in functional dyspepsia. Am J Gastroenterol 111:1853–1854CrossRef

58.

Wouters MM, Balemans D, Van Wanrooy S et al (2016) Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology 150:875–887CrossRefPubMed

59.

Zhou Q, Zhang B, Verne GN (2009) Intestinal membrane permeability and hypersensitivityin the irritable bowel syndrome. Pain 146:41–46CrossRefPubMedPubMedCentral

Titel: Reizdarm und Reizmagen – Pathophysiologie und Biomarker
verfasst von: Prof. Dr. rer. nat. M. Schemann
Publikationsdatum: 03.02.2017
Verlag: Springer Medizin
Schlagwörter: Reizdarmsyndrom
Reizmagen
Biomarker
Erschienen in: Die Gastroenterologie / Ausgabe 2/2017
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI: https://doi.org/10.1007/s11377-017-0143-7

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

PPI reduzieren Blutungsrisiko unter Phenprocoumon

Mitteilungen der Stiftung LebensBlicke

Mitteilungen des BDI

CME: Therapeutische Strategien bei Morbus Crohn

Definitionen des Reizdarmsyndroms

Reizdarm und Reizmagen

Magen-Darm-Erkrankungen in der Hausarztpraxis